Lu Yan-Yan, Huang Xin-En, Xu Lin, Liu De-Gan, Cao Jie, Wu Xue-Yan, Liu Jin, Xiang Jin
Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, China.
Asian Pac J Cancer Prev. 2013;14(3):2005-8. doi: 10.7314/apjcp.2013.14.3.2005.
Pemetrexed (PEM) is effective in first-line treatment for patients with non-squamous non-small cell lung cancer (NSCLC). However there are currently no definitive determinants to certify which patients could benefit from PEM. To improve the efficacy of PEM combined with platinum as first-line therapy for advanced non-squamous NSCLC, we conducted this retrospective study to detect potential determinants of this regimen.
We recruited 109 patients with advanced non-squamous NSCLC who received PEM with a platinum as first-line therapy from June 2006 to February 2013 in Jiangsu Cancer Hospital. Multiple variables (age, sex, smoking, degree of cell differentiation, hemoglobin, platinum drugs combined, positions of metastasis) were selected. Logistic regression analysis was used to analyse relationships between these variables and tumor response.
In univariate analysis, we found that age and platinum significantly influenced the results of PEM therapy (P<0.05). In multivariable analysis, no factors were independently significant.
Our analysis did not suggest that the age, sex, metastasis of liver or other organs, hemoglobin, smoking history and pathological differentiation are associated with the response of PEM. We should conduct further analyses with larger sample size to reconfirm this issue.
培美曲塞（PEM）对非鳞状非小细胞肺癌（NSCLC）患者的一线治疗有效。然而，目前尚无明确的决定因素来确定哪些患者能从PEM治疗中获益。为提高PEM联合铂类作为晚期非鳞状NSCLC一线治疗方案的疗效，我们开展了这项回顾性研究以探寻该治疗方案的潜在决定因素。
我们纳入了2006年6月至2013年2月期间在江苏省肿瘤医院接受PEM联合铂类作为一线治疗的109例晚期非鳞状NSCLC患者。选取了多个变量（年龄、性别、吸烟情况、细胞分化程度、血红蛋白、联合使用的铂类药物、转移部位）。采用逻辑回归分析来分析这些变量与肿瘤反应之间的关系。
单因素分析中，我们发现年龄和铂类显著影响PEM治疗结果（P<0.05）。多因素分析中，无因素具有独立显著性。
我们的分析未提示年龄、性别、肝脏或其他器官转移、血红蛋白、吸烟史及病理分化与PEM反应相关。我们应采用更大样本量进行进一步分析以再次证实该问题。
